MUMBAI:   has acquired  , a US-based specialty pharma company, specialized in marketing of products in the pain management segment. The transaction will be EPS accretive.
 
 With this acquisition, Zydus makes a foray into the specialty pain market in the US valued at $8billion. It gains access to the specialty distribution network and a large prescriber base, says a company statement. This acquisition will also enable the Zydus group to leverage its existing assets in the US.
 Speaking on the development,   CMD Zydus   said, “We have always looked at opportunities that can add value to our operations and the acquisition of   opens up a new business avenue for us in the specialty prescription segment in the US. With a strong commitment to offer effective treatment solutions with a focus on pain management, this new development offers us a platform to launch more specialty products in the US market.”
 
